Erytech Pharma Overview

  • Founded
  • 2004
Founded
  • Status
  • Public
  • Employees
  • 206
Employees
  • Stock Symbol
  • ERYP
Stock Symbol
  • Share Price
  • $6.10
  • (As of Friday Closing)

Erytech Pharma General Information

Description

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.

Contact Information

Website
www.erytech.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Primary Office
  • 60 Avenue Rockefeller
  • Bâtiment Adénine
  • 69008 Lyon
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Erytech Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.10 $5.54 $4.04 - $12.61 $169M 27.3M 467K -$4.54

Erytech Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 138,472 138,472 39,197 (90,919)
Revenue 0 0 0 0
EBITDA (75,412) (75,412) (64,883) (44,346)
Net Income (83,556) (83,556) (70,143) (45,107)
Total Assets 98,892 98,892 132,791 191,994
Total Debt 33,760 33,760 15,821 2,310
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Erytech Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Erytech Pharma‘s full profile, request access.

Request a free trial

Erytech Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of canc
Drug Discovery
Lyon, France
206 As of 2020
00000
00000000 00000

00000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000

00000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ulla
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Erytech Pharma Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
You’re viewing 5 of 63 competitors. Get the full list »

Erytech Pharma Executive Team (13)

Name Title Board Seat Contact Info
Gil Beyen Chief Executive Officer & Board Member
Eric Soyer Chief Financial Officer, Finance & Chief Operating Officer, Operations
Stewart Craig Chief Technology Officer, Technology
Jerome Bailly General Manager & Executive
François Fossiez Ph.D Director, Manufacturing
You’re viewing 5 of 13 executive team members. Get the full list »

Erytech Pharma Board Members (11)

Name Representing Role Since
Gil Beyen Erytech Pharma Chief Executive Officer & Board Member 000 0000
Hilde Windels Self Board Member 000 0000
Jean-Paul Kress MD Self Chairman & Board Member 000 0000
Martine George MD Self Board Member 000 0000
Philipe Archinard Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Erytech Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Erytech Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Erytech Pharma‘s full profile, request access.

Request a free trial